w*******y
发帖数: 60932 | 1 Click Here for Link to go to the OBi110 Amazon Product Page
The popular OBi110 VoIP adapter is selling at $43.99 with FS at Amazon.com
With an OBi you can:Make phone calls in the USA & Canada for free using
Google Voice
Install the OBi out of USA & Canada and make calls to the USA/CAN for 1 CENT!
Port your number to Google Voice for $20
Free Call Waiting, 3-Way Calling, Caller ID, etc.
Free voice mail (with speech to text or email)
Use a secondary VoIP service for E911 like Anveo, Callcentric,... 阅读全帖 |
|
d*****c
发帖数: 23 | 2 有人hold吗？公司的研发还在继续，Multikine的三期可能快开始了。
我转封CVM头的信。现在股价短期适中。
－－－－－－－－－
CEL-SCI Corporation Releases Letter to Shareholders
VIENNA, VA, July 7, 2009 – The following letter is being released by CEL-
SCI Corporation (NYSE AMEX: CVM) to its shareholders:
Dear Fellow Shareholders:
Recently we have been hearing a great deal about the pandemic caused by the
H1N1 swine flu. You may think to yourself, this is no big deal since it
does not seem that serious and, look what happened to bird flu - it
disappear... 阅读全帖 |
|
f**********g
发帖数: 2252 | 3 来自主题: _pennystock版 - vicl SLOW COW.
Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results
in Melanoma
6 hours 15 minutes ago - PMZ
GlobeNewswireVical Incorporated (Nasdaq:VICL) today announced a new
publication summarizing results from the company's completed trials of
Allovectin-7(R) including systemic responses and an excellent safety profile
in patients with metastatic melanoma. An article published in the January
issue of Immunotherapy1 noted that the U.S. incidence of melanoma is
increasing rapi... 阅读全帖 |
|
f**********g
发帖数: 2252 | 4 来自主题: _pennystock版 - vicl SLOW COW.
Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results
in Melanoma
6 hours 15 minutes ago - PMZ
GlobeNewswireVical Incorporated (Nasdaq:VICL) today announced a new
publication summarizing results from the company's completed trials of
Allovectin-7(R) including systemic responses and an excellent safety profile
in patients with metastatic melanoma. An article published in the January
issue of Immunotherapy1 noted that the U.S. incidence of melanoma is
increasing rapi... 阅读全帖 |
|
y*****l
发帖数: 5997 | 5 XenoPort Phase IIb GERD trial fails to meet end point
40 minutes ago - DTM via Comtex
DatamonitorXenoPort, Inc., a biopharmaceutical company, has announced
preliminary top-line results from a Phase IIb clinical trial of arbaclofen
placarbil, or AP, as adjunctive therapy in patients with gastroesophageal
reflux disease, or GERD, who do not experience complete relief of GERD
symptoms while being treated with proton pump inhibitors, or PPI.
In this study, subjects who experienced GERD symptoms desp... 阅读全帖 |
|
D***s
发帖数: 5613 | 6 这个有道理，防止抗药性产生。美华的娃生病见儿医，经常开阿莫西林，10天的药量。
其实3天就见效了。美国那个例子的endpoint是第二天血氧回升到90以上，而法国这个
endpoint是确保virus clearance。
25号会有新闻发布会，可以听听了解一下是什么情况下开始用药，用药后效果是怎样的
。这个病人住院了22天，静脉注射给药了10天，很有可能恶化之后才用药的。
：菌斑文盲有点多啊。我老作为资深码农都知道，这种抗病毒的药，尤其是抑制复制的
，本来就是要长期使用，把病毒数量控制住，再靠自身免疫力完全杀灭的。用十天就好
像用抗生素一定要吃够多少天一样，是防止复发的，不代表用了十天才开始见效。
： |
|
l****z
发帖数: 29846 | 7 By M. Zuhdi Jasser, M.D.
Over the past few years, numerous hearings have already been conducted on
Capitol Hill, in both the House and Senate, looking into domestic Islamist
terrorism and ‘radicalization'. Unfortunately, those hearings garnered
little attention and few tangible results - because they avoided discussing
the root causes. Those hearings instead focused only on "violent extremism"
a useless concept addressing a symptom and not the disease. Up to now the
combined efforts of the force... 阅读全帖 |
|
e**n
发帖数: 304 | 8 It is the famous Vertex Cover problem,
Branch and bound works great for this problem.
For any edge, one of the endpoints would be in the
optimal solution. Try all possible combination of
the endpoints of the edges, it would be a
2^k algorithm where k is the size of the solution.
terminating |
|
e****t
发帖数: 766 | 9 也报个offer，临床统计， PhD, experienced. 工作从7月份开始找到现在， 主
要是当前工作的公司在裁人，安全起见， 所以开始骑驴找马。 Recruiter 电话很多，
但是到HM 只有5个， 三个onsite， 1 个offer。 也算圆满了。工资少了些， 主要是
离LD 从250 mile 变成 90 mile， 钱不是很重要了。 有点遗憾的是， 绿卡又得从新
开始了。
还记得一些面试题， 回馈本版， 谢谢其他贴面经的朋友。
Linear regression: basic assumptions, how to diagonistic,
if violate any assumption, how to handle
Bootstrap basic idea.
Bayesian theory/Frequetist difference. How to explain to non statistician.
What is empirical Bayesian?
What is difference between logrank test and wilco... 阅读全帖 |
|
h*******l
发帖数: 22 | 10 对静态interval set：（leetcode上的）
排序，nlgn
过一遍， n
动态的（不停有interval 插入）
方法一：
每个新的都插入到正确的位置，lgn
再过一遍，n
结果是n^2 的
方法2：
2.1 假设知道所有end points，比如1--1000000，每个点都是可能的endpoints
根据end point 建segment tree
每个新的插入需要lgn
总共nlgn
2.2 不知道end points
完全动态的segment tree，每次插入需要rebalance （O(1)）
修改union lgn
插入endpoints lgn
总共nlgn
这个就比较复杂了， 感觉面试仅停留于静态的就不错了
|
|
s**x
发帖数: 7506 | 11 you are right.
see update #26 in http://www.mitbbs.com/article_t1/JobHunting/32569901_0_2.html.
initially I thought they want the volume sum.
for volume max, looks like you need to maintain a max heap or a BST when you
are scanning the endpoints.
the problem for max heap is that it is a little tricky to remove the
endpoint element from the heap.
For balanced BST, you can find the max and remove an element with O(logn),
so not bad. |
|
s**x
发帖数: 7506 | 12 you are right.
see update #26 in http://www.mitbbs.com/article_t1/JobHunting/32569901_0_2.html.
initially I thought they want the volume sum.
for volume max, looks like you need to maintain a max heap or a BST when you
are scanning the endpoints.
the problem for max heap is that it is a little tricky to remove the
endpoint element from the heap.
For balanced BST, you can find the max and remove an element with O(logn),
so not bad. |
|
x*********a
发帖数: 36 | 13 来自主题: JobHunting版 - F家题请教 网上看的，说是F家的，哪位大侠说说怎么答？
Suppose we are given a set L of n line segments in the plane, where the
endpoints of each segment lie on the unit circle x^2 + y^2 = 1, and all 2n
endpoints are distinct. Describe and analyze an algorithm to compute the
largest subset of L in which no pair of segments intersects |
|
L***s
发帖数: 1148 | 14 用nodejs写的web front-end server的代码，和桌面browser端的js app，
逻辑上是紧耦合的，常常放到一个js repo里，
不然是没法写end-to-end integration tests的。
java可能是web front-end server app下面提供restful endpoint的。
复杂的SOA web架构，下面可能有2-4层restful endpoints，每层用什么语言都可能。 |
|
i***e
发帖数: 9429 | 15 刚才点错个位置，下载了个软件， Symantech EndPoint 自动测到5个virus,那个软件
uninstall 了，virus 也撤除了， 不过restart 后，endpoint 还是提醒有virus,但没
显示出来是啥， 现在在做FULL SCAN，还没发现啥， 电脑没事吧？还有啥要注意的？ |
|
g****e
发帖数: 1426 | 16 From my blog:
http://www.mitbbs.com/pc/pccon_12673_256059.html
TSRX -- current at 4.45
It is still in down trend, it seems will go to 4. Once the share price
stable, will load.
Catalyst event:
"As with our ESTABLISH 1 study, ESTABLISH 2 was designed to prepare
tedizolid for
registration globally by capturing both the new and former FDA endpoints as
well as the
European endpoints for ABSSSI," said Jeffrey Stein, Ph.D., President and
Chief
Executive Officer at Trius. "We remain on schedule to repo... 阅读全帖 |
|
c*****l
发帖数: 739 | 17 Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Enter Into
Technology Development Agreement for ThermoDox� for the Greater China
Territory - MarketWatch
LAWRENCEVILLE, N.J. and TAIZHOU CITY, China, Jan. 22, 2013 /PRNewswire via
COMTEX/ -- Celsion Corporation CLSN -81.17% , a leading oncology drug
development company, and Zhejiang Hisun Pharmaceutical Company Ltd. (sse
code:600267), a leading Chinese pharmaceutical company, today announced that
they have entered into a techno... 阅读全帖 |
|
b*****p
发帖数: 9649 | 18 FDA tells Sarepta new drug filing for eteplirsen 'premature'
Sarepta provided an update on its discussions with the FDA regarding its
planned New Drug Application submission and confirmatory clinical study with
eteplirsen for the treatment of Duchenne muscular dystrophy. Citing recent
developments since Sarepta's last meeting with the agency, including a
failed study with a competitive product and recent natural history data in
DMD, the FDA indicated the new data raise "considerable doubt" about... 阅读全帖 |
|
s*******d
发帖数: 3786 | 19 CF101 did not meet the primary efficacy endpoint of complete clearing of
corneal staining, nor the secondary efficacy endpoints. Nonetheless, CF101
was found to be well tolerated. |
|
V*****2
发帖数: 7930 | 20 You can and should read Blank's entire Northera review. Here are key,
summary excerpts:
In summary, in support of approval, there is one trial (Study 301) that is
strongly supportive of efficacy of droxidopa and contains many of the
attributes of a single trial that might stand alone to support efficacy:
large and multicenter trial, improvement on multiple ordered endpoints
including OHSA Item 1, OHQ and systolic blood pressure, and statistically
very persuasive findings. From a post-hoc analysi... 阅读全帖 |
|
P**B
发帖数: 1051 | 21 The FDA has further informed us that data from short-term endpoints
measuring symptomatic benefits may be sufficient evidence of efficacy as
required for approval and that durability of response, determined by
endpoints measuring long-term symptomatic benefits, may be studied and
demonstrated in post-approval study or studies |
|
x*z
发帖数: 1010 | 22 ft,偶老不常看review，不过偶老原来工作就是负责benchmarking，performance
optimization，跟vendor compete world records之类的。现在工作角色变了，但是
还是有10～30%的分量。这个盘子现在已经快满了，不是做benchmarking的料了，随便
测了测（无优化），另外这个记错了一点，不是WD，是Maxtor Onetouch
root@moo:# df -i /dev/sde
Filesystem Inodes IUsed IFree IUse% Mounted on
/dev/sde 110655152 521408 110133744 1% /media/bar
root@moo:# df -h /dev/sde
Filesystem Size Used Avail Use% Mounted on
/dev/sde 466G 440G 27G 95% /media/bar
root@moo:# d... 阅读全帖 |
|
j*******n
发帖数: 4 | 23 最近有个需求，就是要给几个http request写个R language的SDK来发出这好几个http
request。
要写的http request太多了，而且end point还在调整，所以打算走代码生成的路
试了一下这个package的R-sdk generator，确实能用，打算就用这个：
https://github.com/Kong/httpsnippet
在尝试用scala来parse Postman collection echo endpoint那37 个request做test
cases。
这里有个网站，把postman collection echo endpoint的json export出来，复制粘贴
，就可以生成case class：
https://transform.tools/json-to-scala-case-class
但是要怎么要才能处理 整个json呢？因为postman json里面的case class存在
optional，试了play json，感觉没搞出来，有大牛愿意给个代码指导一下吗？
这里提供一个driver code：
... 阅读全帖 |
|
l***y
发帖数: 791 | 24 em, definately there can be some more inteligent 'application routers'
to handle the problems NAT generates. apps using protocols such as SIP, FTP,
etc,
refer to the private ip of the endpoints behind NAT, this'll break the
applications unless some measure is taken to handle NAT. either the router
can re-write the signalling packets to replace private ips with public ip,
or the endpoints have to be aware and handle NAT, or ...
NAT can be single ip to single ip, btw, doesn't have to be multiple i |
|
m*********e
发帖数: 37 | 25 Hi guys,
When I am using the same sample from msdn, as:
____________________________________________________
// Establish the local endpoint for the socket.
IPHostEntry ipHost = Dns.GetHostEntry(Dns.GetHostName());
IPAddress ipAddr = ipHost.AddressList[0];
IPEndPoint ipEndPoint = new IPEndPoint(ipAddr, 11000);
// Create a TCP socket.
Socket client = new Socket(AddressFamily.InterNetwork,
SocketType.Stream, ProtocolType.Tcp);
// Connect the socket to the remote endpoint.
client.Connect(i |
|
d******r
发帖数: 5008 | 26 同一个method 内加一个，删一个，这个可以保证吧。
LZ的目的是不让buffer无限度增加，不是一定要一个稳定的
Size，一个data entry 就两个数，handle 几百个线程同写
也没多大呀。而且LZ是要保存一定时间内的data。
如果一秒内buffer就过上限被删了，你用其它方式也解决
不了丢数据的问题。
如果这个data只是存比如每5分种所有endpoint
的平均值的话，也就是说，RTT的平均值跟endpoint数量
有关，但data是每几分钟统计并存一次，你这个问题
就根本不存在。
】
办？
entry |
|
N******o
发帖数: 3053 | 27 Lab给买的台式机，学校IT部门的人简直就应该吃点屎补补脑子。新机子拿去装一些安
全软件什么，同时做一个ISO备用，用了两个多星期。拿回来一看，猪们把Win7 64位降
到XP 32位，所以买的16G内存被32位只能认到4G，买的500G+500G硬盘，被XP只能认到
500G+40G。
给硬塞进一个McAfee Endpoint Encryption，这玩意简直就是病毒，硬盘狂闪，三代i7
被它搞得基本上干不了什么。进Local Service关了它。后来Office Outlook有点问题
，于是修复，重启。McAfee Endpoint Encryption生气了，挂了，说被Corrupted了。
放狗一看，麻烦的要死，还有失去所有Data可能。日啊，学校IT又拿去折腾了。
以前在federal government时候认为安全等级应该是最高了，到了这个不入流大学，学
校的行政以及Support部门，它们的主要职能就是给你找麻烦。来了一个半月了，电脑
都没有搞掂。要不是Lab老板的才能，鬼才会来这个穷乡僻壤，不入流的大学。康州真
是个鬼地方。 |
|
p******e
发帖数: 247 | 28 functional observational battery endpoints
quantitative motor activity,
scheduled-controlled operant behavior endpoints
这几个具体的中文名称是什么？
多谢！ |
|
k******n
发帖数: 133 | 29 You are right. It's a phase III trial with a surrogate endpoint. But I still
don't think it will affect its indition for other cancers, as other trials
used overall suvival as the endpoint.
approval
phase
of |
|
s*****0
发帖数: 357 | 30 你的project purpose就是data dredging? 如果不是，什么是你的primary/secondary
endpoint? 那些是跟endpoint相关的factors? 不筛选一下，就区区200个病人，要多少
层stratification？
should |
|
b*******n
发帖数: 8420 | 31 这话偏激了。很多化学类药物在上市之后很长一段时间都不知道具体的药理，但是只要
安全有效就行。
对于临床试验，不一定非要找到某个分子细胞水平的endpoint来评估。爬六楼不喘气之
类的“宏观性”的生理指标也是可以作为endpoint的。 |
|
l**********1
发帖数: 5204 | 32 >having a clear endpoint
换位思考下,
癌症晚期的可以用其癌症潜伏期就预存液氮中的体细胞克隆一个她或他吗?
这不治愈了前一个个体的绝症了不? 今后全克隆人的世界=Bio/Medi reached a clear
endpoint |
|
s**********y
发帖数: 509 | 33 说的就是基础， 要对自己有清醒的认识：
（1） 做基础的人社会并不需要许多。
（2） 基础项目优先权一般不高。 大家要问问自己： 我为什么现在要做这个? 或者为
什么funding agency 现在要fund这个？
还是回到最初的讨论： 年青人如何才能避免在漫长的生物研究生态链中做螺丝钉？
研究要有明确的endpoint， endpoint 要能够定量说明。
NIH 砸下1米， 它也想知道你的目标是什么？ 你如何知道你达到你的目标是吧？
funding agency 砸钱听你天天编故事，您要觉得如此好事能老您头上， 您随意哈。 |
|
D*a
发帖数: 6830 | 34 不不不，这是一个逻辑问题。
你认为需要endpoint才能有成绩，那么才要看这些做出成就来的炸药奖是否有endpoint
，我如果举一些没有成绩的人，那么逻辑上有什么意义呢？
请不要把这个局限在我身上，你一开始立意高远，直指整个生物界，这没出一页，就变
成了我这单个人如何如何，这也太小家子气了是不？ |
|
s******c
发帖数: 331 | 35 这一段深得我心，虽然我也觉得搞个endpoint啥的很不靠谱，不过确实基础研究的
priority不高，想从NIH拿钱，确实得有明确的目标。
对于policy的制定者来说，这是一个dilemma，或者说需要很好的balance，因为没有半
盲目性的基础研究，就容易使translational research陷入全盲目性。有名的例子很多
，比如以前各大公司轰轰烈烈的搞Ras inhibitor的药去治cancer，结果clinical
trials做了一堆，没一个搞成的，还是后来基础研究的推进发现以前Ras signaling的
复杂性，以前的大方向都是错的，听一个报告说一个有名的做cancer的开玩笑，说如果
浪费在ras上的钱去搞其他的，说不定已经攻克几种cancer了（当然也只是玩笑）。其
它的基础研究推进新的治疗手段，新的检测手段，新的药物靶点，新的药物筛选方法等
等的例子不要太多，那些动不动就说做生物发paper都是骗钱都是无用发100片NCS也不
如一个码工的都是怨妇之语，不用当真。说起来，其实很大的disappointment在cancer
领域，投的钱非常多，但是fai... 阅读全帖 |
|
p******e
发帖数: 247 | 36 【 以下文字转载自 Biology 讨论区 】
发信人: panewpee (什么样的眼睛看见什么样的世界), 信区: Biology
标 题: 请教几个英文术语
发信站: BBS 未名空间站 (Wed May 26 15:18:13 2010, 美东)
functional observational battery endpoints
quantitative motor activity,
scheduled-controlled operant behavior endpoints
这几个具体的中文名称是什么？
多谢！ |
|
s*********x
发帖数: 67 | 37 同意LZ的看法,FDA和EMA对于risk benefit profile的评审已经达到非常细致的程度了,
对不同TA的药物要求甚至会相差很大,所以不能和原文作者描述的那样一概而论.
原文作者把临床实验的设计想得过于简单:
1.首先是TA不同要求不同:
比如oncology对于I\II\III的要求,某些方面就比较宽松,可以使用一些surrogate
endpoint,临床样本也相对比较小(当然这个也和统计要求的power和non-inferiority
margin有关)
但同时如果你看cardiovascular, 患者样本量很多都是成千上万,对于risk/benefit
asseement的要求也不一样,对于primary endpoint要求也常见全因死亡这种大终点,很
少有surrogate
2."临床试验是在一定的人群中进行，而不同的人群对实验化合物或者生物制品（比如
说疫
苗）的反映可能不同，所以即使是在整个人群中效果不好，而在某些人群中效果好，但
FDA不会因在某些人群中效果好就批准这个实验化合物或者生物制品，就是要根据原来
设计时的人群来看结果"
LA所说的"某些人群... 阅读全帖 |
|
s*r
发帖数: 2757 | 38 whether you can use linear regression depends on the distribution of the
endpoint (conditional upon X)
if your endpoint is binary, google armitage trend
continuous |
|
g******n
发帖数: 339 | 39 Your stand points always seem to be different from most people.
Anyway, how to analyze the data really depends on the endpoint of the study-
-I would assume that the blood pressure will be the endpoint. In clinical
trials, people are often interested in the change from baseline to the end
of treatment period (often very short period such as 4 weeks, or 8 weeks)in
24 hours mean systolic or diastolic blood pressure(SBP or DBP). The 24 hour
SBP or DBP in general have to be derived based on all meas |
|
s*r
发帖数: 2757 | 40 "那我们分析大脑数据的时候，把这N个病人当成random sample；分析心脏方面的时候
，还是。"
what is wrong with this.
你又不是同时分析大脑和心脏.
it may become a problem if you want to establish certain family wise type I
error across endpoint: one obvious issue is bonferroni may be over-
correction. on the other hand, if you really want to establish a
significance between one X variable and many endpoints, you should run a
repeated measure analysis. |
|
j*****3
发帖数: 6 | 41 Anyone interested please send resume to j************[email protected] or apply
through the following link:
http://careers.peopleclick.com/careerscp/client_medtronic/exter
Position Description
To participate in the planning, implementation and coordination of the
design of protocols, case report forms, and clinical procedures for the
efficient data collection, management and evaluation of clinical studies
conducted by the business unit, and to execute the analysis of data from
these studies. To partic... 阅读全帖 |
|
